Patient-derived xenografts: A platform for accelerating translational research in prostate cancer.
Recently, there has been renewed interest in the development and characterization of patient-derived tumour xenograft (PDX) models. Numerous PDX models have been established for prostate cancer and, importantly, retain the principal molecular, genetic, and histological characteristics of the donor tumour. As such, these models provide significant improvements over standard cell line xenograft models for biological studies, preclinical drug development, and personalized medicine strategies. This review summarizes the current state of the art in this field, illustrating the opportunities and limitations of PDX models in translational prostate cancer research.
Vancouver Prostate Centre, Vancouver, BC, Canada; Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Alastair H
AH
Davies
Vancouver Prostate Centre, Vancouver, BC, Canada; Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Yuzhuo
Y
Wang
Vancouver Prostate Centre, Vancouver, BC, Canada; Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: azoubeidi@prostatecentre.com.
Amina
A
Zoubeidi
D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D057285:Precision Medicine; D011471:Prostatic Neoplasms / Q000473:pathology*; D057170:Translational Research, Biomedical; D023041:Xenograft Model Antitumor Assays
D014408:Biomarkers, Tumor
Cancer models; Drug discovery; Patient-derived xenograft; Personalized medicine; Prostate cancer; Translational research